GKT137831: Selective Dual Nox1/Nox4 Inhibitor for Oxidative Stress Research

Executive Summary: GKT137831 (APExBIO SKU B4763) is a potent and selective inhibitor of NADPH oxidase isoforms Nox1 and Nox4, with Ki values of 140 nM and 110 nM, respectively [APExBIO Product Page]. This compound reduces intracellular reactive oxygen species (ROS) production, modulates Akt/mTOR and NF-κB signaling, and affects key fibrotic and inflammatory mediators such as TGF-β1 and PPARγ (Yang et al., 2025). In vivo, oral administration (30–60 mg/kg/day) attenuates pulmonary vascular remodeling, right ventricular hypertrophy, liver fibrosis, and diabetes-accelerated atherosclerosis in mouse models (Advanced Insights, 2023). GKT137831 is soluble in DMSO (≥39.5 mg/mL), recommended for storage at -20°C, and typically used at 0.1–20 μM for 24-hour incubation [APExBIO]. Clinical studies underscore its translational potential for diseases driven by oxidative stress (Redefining Redox, 2023).

Biological Rationale

Reactive oxygen species (ROS) are critical mediators of cellular signaling and pathogenesis. NADPH oxidase isoforms Nox1 and Nox4 are major enzymatic sources of ROS in vascular, hepatic, and metabolic tissues (Yang et al., 2025). Overproduction of ROS contributes to chronic inflammation, fibrosis, vascular remodeling, and progression of diabetes-related complications. Traditional antioxidants lack specificity and may disrupt physiological redox homeostasis. Selective inhibition of Nox1 and Nox4 offers a targeted approach for modulating pathological ROS without broadly suppressing essential redox signaling (Mechanistic Insights, 2023). By focusing on the enzymatic sources, agents like GKT137831 provide greater experimental and therapeutic precision.

Mechanism of Action of GKT137831

GKT137831 is a small-molecule inhibitor that binds to Nox1 and Nox4, preventing the transfer of electrons from NADPH to molecular oxygen, thereby reducing the formation of superoxide and hydrogen peroxide. Inhibition constants are 140 nM (Nox1) and 110 nM (Nox4), reflecting high selectivity (APExBIO). GKT137831 reduces hypoxia-induced H₂O₂ release in vitro, and decreases proliferation of human pulmonary artery endothelial cells (HPAECs) and smooth muscle cells (HPASMCs) (Yang et al., 2025). Downstream, the compound modulates key signaling pathways:

• Inhibits Akt/mTOR signaling, affecting cell survival and proliferation
• Suppresses NF-κB activation, reducing inflammatory gene expression
• Decreases TGF-β1 and increases PPARγ expression, impacting fibrosis and metabolic regulation

These effects are concentration-dependent and reproducible in multiple cellular and animal models.

Evidence & Benchmarks

• GKT137831 inhibits ROS production by Nox1/Nox4 in cell-free and cellular systems (IC₅₀: 140 nM for Nox1; 110 nM for Nox4) (APExBIO).
• Reduces hypoxia-induced H₂O₂ release in HPAECs and HPASMCs within 24 hours at 1–20 μM (Yang et al., 2025).
• Attenuates pulmonary vascular remodeling and right ventricular hypertrophy in mouse models after oral dosing (30–60 mg/kg/day, 2–4 weeks) (Advanced Insights, 2023).
• Suppresses NF-κB–mediated inflammation and TGF-β1–driven fibrosis in vivo and in vitro (Redefining Redox, 2023).
• Shows moderate to high solubility in DMSO (≥39.5 mg/mL) and moderate solubility in ethanol (≥2.96 mg/mL with warming) (APExBIO).

For practical assay guidance and enhanced reproducibility, see the scenario-focused article "Optimizing Oxidative Stress Assays with GKT137831", which this article extends by providing a systematic, mechanistic review and structured evidence mapping.

Applications, Limits & Misconceptions

GKT137831’s unique dual Nox1/Nox4 selectivity enables a broad spectrum of applications in oxidative stress research and translational disease models:

• Investigating mechanisms of pulmonary vascular remodeling and right ventricular hypertrophy
• Modeling liver fibrosis and diabetes-accelerated atherosclerosis
• Dissecting redox-driven Akt/mTOR and NF-κB pathway modulation
• Testing targeted anti-fibrotic or anti-inflammatory strategies in vivo

For a deeper dive into translational opportunities and integration with emerging redox biology, see "Redefining Redox: Strategic Dual Nox1/Nox4 Inhibition with GKT137831". This article clarifies the boundaries of GKT137831’s performance, especially regarding target selectivity and clinical translation.

Common Pitfalls or Misconceptions

• GKT137831 does not inhibit all NADPH oxidase isoforms; Nox2 and Nox5 activity is not significantly affected under standard conditions.
• The compound is not water-soluble; improper dissolution can lead to inconsistent dosing or assay artifacts (APExBIO).
• Long-term storage of GKT137831 solutions (>1 week) can result in loss of potency.
• Observed effects at concentrations >20 μM may reflect off-target or cytotoxic effects, not specific Nox1/Nox4 inhibition.
• GKT137831 is not a pan-antioxidant; non-enzymatic sources of ROS are unaffected.

For further mechanistic context, consult "GKT137831: Mechanistic Insights and Next-Gen Applications", which this article updates by focusing on recent in vivo benchmarks and workflow integration.

Workflow Integration & Parameters

GKT137831 is supplied by APExBIO as a powder (SKU B4763) and should be dissolved in DMSO at concentrations ≥39.5 mg/mL or ethanol (≥2.96 mg/mL with warming and sonication). The compound is insoluble in water. Store powder at -20°C and avoid repeated freeze-thaw cycles. For in vitro assays, recommended working concentrations are 0.1–20 μM with a typical incubation time of 24 hours. For in vivo experiments, oral dosing of 30–60 mg/kg/day is standard practice in mouse models. Confirm compound efficacy by quantitative ROS assays and endpoint readouts (e.g., cell proliferation, fibrosis markers). For robust assay design, see "GKT137831: Dual Nox1/Nox4 Inhibitor for Oxidative Stress Research", a complementary guide to integrating GKT137831 into redox-focused workflows.

Conclusion & Outlook

GKT137831 is a benchmark tool for dissecting the role of Nox1 and Nox4 in pathological ROS production, inflammation, and fibrosis. Its high specificity, robust in vitro and in vivo validation, and translational promise position it as an essential asset for oxidative stress research. APExBIO’s formulation (SKU B4763) ensures reproducibility and compatibility with a range of experimental models. As evidence accumulates, GKT137831 is poised to enable new therapeutic strategies for oxidative stress–driven diseases. For product details and ordering, visit the APExBIO GKT137831 product page.